Sahaquine, a selective HDAC6 inhibitor, reduced the level of p-glycoprotein and EGFR activity and enhanced the sensitivity of glioblastoma to anti-cancer cancer drugs such as TMZ, quercetin, and buthionine sulfoximine [68] (Figure 4A). This evidence concerns the gene HDAC6 and cancer.